Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16053233 | 1.00 | CES2 (0.45) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL24579284 | 0.82 | CES2 (0.43) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL11744885 | 0.82 | CES2 (0.48) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL17266590 | 0.82 | CES2 (0.43) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL13767001 | 0.80 | CES2 (0.50) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL9235066 | 0.80 | CES2 (0.42) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL30729426 | 0.78 | CES2 (0.48) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL8429753 | 0.78 | TSHR (0.45) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL8429754 | 0.78 | TSHR (0.45) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL2187634 | 0.77 | CES2 (0.46) | CES2CES1ALDH1A1POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016860-A1 | METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS | DUBLIN CITY UNIVERSITY (IE) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016860-A1 | METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS | DCXR, TECR, PWWP2B | CES2 2281/4885CES1 2990/4885ALDH1A1 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.